Glenmark Pharmaceuticals to launch Brukinsa (zanubrutinib) in India after DCGI approval, offering treatment for five B-cell blood cancers with fewer cardiac side effects and flexible dosing options.

Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following ...

Glenmark-Ichnos cancer drug shows 74% response in phase-1 trial The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients with ...

Glenmark’s myeloma drug delivers high response in phase-1 trial At active dose levels (≥ 50 µg/kg), 26 of 33 evaluable patients (79%) achieved objective responses, including stringent or ...

Glenmark Pharmaceuticals Ltd Summary. Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977. The Company is actively involved in the discovery of new molecules both NCEs (new ...

Check out our GLENMARK stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.

Glenmark Life Sciences Ltd Summary. Alivus Life Sciences Limited was initially established as Zorg Laboratories Private Limited, on June 23, 2011 and was granted the Certificate of Incorporation ...

Karin Brulliard is a Colorado-based national reporter covering the American West. Previously, she was an international news editor; a foreign correspondent in South Africa, Pakistan and Israel ...

Palviya also recommends buying Glenmark Pharma at Rs 1,406 with a stop loss at Rs 1,387 and target price at Rs 1,445.

Glenmark Pharmaceuticals Ltd News - Get all latest breaking news & updates on Glenmark Pharmaceuticals Ltd from The Hindu BusinessLine . SENSEX 81,118.60 -573.38. NIFTY 24,718.60 ...

Find out if Glenmark Pharmaceuticals Ltd (GLENMARK:XNSE) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of ...